The Federation of Obstetric and Gynaecological Societies of India (FOGSI) has published an expert consensus endorsing Elagolix as a meaningful addition to the therapeutic options for women with moderate-to-severe endometriosis-associated pain. The guidance follows a specialist meeting where leading gynaecologists assessed clinical trial data and real-world experience with the first oral, non-peptide GnRH antagonist.
Elagolix for endometriosis: mechanism and dosing
Elagolix competitively blocks pituitary gonadotrophin-releasing hormone receptors, producing a rapid, dose-dependent reduction in circulating oestrogen without the initial flare effect associated with GnRH agonists. The drug offers two principal regimens: 150 mg once daily, which achieves partial oestrogen suppression and is intended to maintain oestrogen in an effective yet bone-safe range; and 200 mg twice daily, which produces near-complete suppression suitable for severe dysmenorrhoea, non-menstrual pelvic pain, dyspareunia and deep infiltrating disease.
FOGSI experts highlighted that the availability of an oral antagonist provides clinicians and patients with more flexible treatment options, particularly for those who prefer to avoid injectables or who require rapid symptom control.
Evidence on efficacy and tolerability
A recent systematic review and meta-analysis referenced by the consensus found that Elagolix produced greater relief from dysmenorrhoea than a range of comparators, including injectable GnRH antagonists, injectable GnRH agonists, progestins and combined oral contraceptives. In addition, Elagolix monotherapy showed better improvement in dyspareunia compared with GnRH analogues given with add-back therapy.
Regarding tolerability, the consensus noted a generally favourable safety profile. Reported adverse effects are typically mild and dose dependent, the most common being hot flushes and headache. There is a lower incidence of breakthrough bleeding compared with some alternatives. Effects on bone mineral density (BMD) are small and correlated with dose and duration; importantly, the reductions observed in trials were largely reversible after treatment cessation and no new long-term safety signals have emerged.
Clinical implications for practice in India
FOGSI advised that Elagolix can be considered as an emerging first-line therapeutic option in selected patients with endometriosis, particularly those with moderate-to-severe pain who need rapid symptom relief or who seek an oral regimen. The consensus recommends individualised decision making that weighs symptom severity, fertility plans, BMD baseline, and patient preference.
Practitioners are encouraged to monitor bone health when using higher doses or prolonged courses, and to consider add-back hormone therapy where clinically appropriate. The group also emphasised the role of shared decision making and counselling on expected benefits and side effects.
As endometriosis remains a leading cause of chronic pelvic pain and impaired quality of life for many women, FOGSI’s endorsement of Elagolix broadens the array of evidence-based options available to Indian clinicians and their patients. Wider adoption will depend on access, cost considerations and continued post-marketing surveillance to confirm long-term outcomes in diverse populations.
Key Takeaways:
- FOGSI issues expert consensus supporting Elagolix as an effective oral GnRH antagonist for moderate-to-severe endometriosis pain.
- Two dosing options allow partial suppression (150mg once daily) or full suppression (200mg twice daily) to target different symptom severities.
- Systematic review and meta-analysis show superior relief in dysmenorrhoea and dyspareunia compared with several existing therapies.
- Elagolix is generally well tolerated with dose-dependent, reversible effects on bone mineral density and manageable side effects.
